Zai Lab Ltd

Zai Lab is a commercial-stage biopharmaceutical company that develops and commercializes therapies for oncology, autoimmune disorders, neuroscience, and infectious diseases. Its commercial portfolio features licensed therapies including ZEJULA for ovarian cancer, VYVGART and VYVGART Hytrulo for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy, NUZYRA for pneumonia and skin infections, and OPTUNE for glioblastoma. The company also markets QINLOCK for gastrointestinal stromal tumors, XACDURO for hospital-acquired bacterial infections, and AUGTYRO for solid tumors and non-small cell lung cancer. Its customers include medical centers, distributors, and adult patients requiring specialized treatments.

Geographically, the company maintains operations in Greater China and the United States, with commercial sales teams covering major medical centers in mainland China, Hong Kong, Macau, and Taiwan. The business operates seven approved commercial programs alongside internal research and development activities and clinical trial collaborations across China and the United States. The provided text does not state the location of its corporate headquarters.

Summary of the business section of Zai Lab's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of January 31, 2026, we had 1,784 full-time employees, of which 1,710 were located in Greater China.”